The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Correlation of high levels of HER2 measured by multiplex mass spectrometry with increased overall survival in patients treated with anti-HER2-based therapy.
Paolo Nuciforo
No relevant relationships to disclose
Sheeno P Thyparambil
Employment or Leadership Position - OncoPlex Diagnostics
Stock Ownership - OncoPlex Diagnostics
Ana Christina Garrido-Castro
No relevant relationships to disclose
Vicente Peg
No relevant relationships to disclose
Ludmila Prudkin
No relevant relationships to disclose
Jose Jimenez
No relevant relationships to disclose
William Arthur Hoos
Consultant or Advisory Role - OncoPlex Diagnostics
Jon Burrows
Employment or Leadership Position - OncoPlex Diagnostics
Stock Ownership - OncoPlex Diagnostics
Todd A. Hembrough
Employment or Leadership Position - OncoPlex Diagnostics
Stock Ownership - OncoPlex Diagnostics
Jose Manuel Perez-Garcia
No relevant relationships to disclose
Javier Cortes
No relevant relationships to disclose
Maurizio Scaltriti
No relevant relationships to disclose